European Authorities Approve JHL Biotech's Clinical Trial Application for Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

HSINCHU, Taiwan and WUHAN, China, March 1, 2018 /PRNewswire/ -- JHL Biotech announced that the Dutch Healthcare Authority has approved a Clinical Trial Application for JHL's dornase alfa biosimilar, JHL1922, to improve pulmonary function of cystic fibrosis patients. The Phase I clinical...

from PR Newswire: //http://ift.tt/2F8MF5K